A group of retina specialists developed and published a new consensus-based classification system for nonadherence and nonpersistence to anti-VEGF therapies in neovascular age-related macular degeneration.
The study provides the framework for more consistent assessment, reporting and comparison of real-world patient engagement and outcomes of therapy.
“We also proposed a classification of factors affecting nonadherence and nonpersistence. Studies often group patients together and don’t look at their specific reasons, which cover a wide range from lack of response to the treatment to